#Switzerland #Cerbios-Pharma #HAS Healthcare #Biasca #CDMO sector

A New Era in the CDMO Industry

In a significant move within the pharmaceutical landscape, HAS Healthcare Advanced Synthesis SA (HAS) has executed a major acquisition of Cerbios-Pharma SA, aiming to establish a world-leading group in the Contract Development and Manufacturing Organization (CDMO) sector. This strategic merger, fueled by the support of 65 Equity Partners, signifies a pivotal moment for both organizations, enhancing their production capabilities and expertise, and providing a solid foundation for substantial growth.

Who are the Players Involved?

HAS Healthcare, a prominent name in the development and production of active pharmaceutical ingredients (APIs), particularly high-potency variants and anticancer compounds, is set to amplify its global reach through this acquisition. Cerbios-Pharma, renowned for its excellence in manufacturing chemical and biological APIs, complements HAS's offerings, especially in the rapidly expanding field of antibody drug conjugates (ADCs).

Both companies share a commitment to maintaining high standards and technological advancement, which positions them to evolve as leaders in the CDMO sector. The merger will not only combine their existing capabilities but is also expected to foster innovation, ultimately enhancing their service delivery to clients worldwide.

The Strategic Backbone

The merger marks the entry of 65 Equity Partners as a significant stakeholder with approximately 40% ownership, alongside the continued majority control held by the Braglia family. This investment group focuses on nurturing family-owned businesses and fostering long-term growth through sustainable practices. Their backing ensures that both HAS and Cerbios can pursue aggressive growth strategies while preserving core values that define their operations.

Strengthening the Pharmaceutical Ecosystem

By merging, HAS and Cerbios are not just creating a powerful entity but are also reinforcing the reputation of the Ticino region as a central player in the global pharmaceutical and chemical industries. As the market experiences rising demands for complex therapies, including those targeting oncology, neurology, and rare diseases, the combined expertise of both companies uniquely positions them to meet these challenges effectively.

Riccardo Braglia, CEO of 3B Future Holding SA and Board Member of HAS, expressed enthusiasm for the merger, pointing out that it is a vital step in their global expansion strategy. Noting that each company brings complementary skills to the table, he believes this collaboration will enhance their ability to provide innovative, customized solutions to their clients.

Future Growth Opportunities

The CDMO sector is anticipated to see strong growth driven by demographic shifts, scientific advancements, and increasing requirements for advanced therapies. This merger reflects an understanding of these drivers and positions HAS and Cerbios to not just adapt but thrive amidst evolving market dynamics.

Leadership from both companies has indicated that their corporate cultures, underscored by family ownership, will remain integral to their continued success. The fusion aims to cultivate a collaborative workforce of over 400 professionals committed to pushing boundaries in pharmaceutical development and production.

Commitment to Technological and Operational Excellence

As part of the merger strategy, both HAS and Cerbios remain dedicated to investing in technological advancements and operational excellence. The companies will operate under strong regulatory frameworks, delivering top-quality products that meet international health standards. Their production facilities are consistently monitored by organizations like SwissMedic and the FDA, ensuring adherence to Good Manufacturing Practices (cGMP).

The groundwork has been laid for exciting prospects ahead of both HAS and Cerbios as they endeavor to lead in the CDMO space. With their strategic vision and commitment to innovation, they are poised for significant growth and impactful contributions to the healthcare industry, promising more than just expansion but a transformation in how pharmaceuticals are developed and manufactured.

Looking Ahead

As they move forward, HAS and Cerbios plan to maintain their core principles of quality, innovation, and customer-centric solutions. With the strategic guidance of 65 Equity Partners, they are set to explore new markets, enhance client engagement, and pursue select acquisitions that align with their growth objectives. This merger is not only a milestone for the companies involved but also for Ticino, establishing a robust hub for pharmaceutical innovation on a global scale.

Together, HAS Healthcare and Cerbios-Pharma are ready to set new benchmarks in the pharmaceutical landscape, combining their heritage, values, and vision to redefine success in the CDMO sector. This merger serves as a testament to the potential of strategic alignments in driving forward the healthcare industry in dynamic and impactful ways.